



MDRP & BEST PRICE POLICY, EXPLORING POSSIBLE SOLUTIONS AND RECOMMENDATIONS

ALEJANDRO DREVON


GENERAL MANAGER ABBVIE PUERTO RICO

LEAD FOR HEALTHCARE OUTCOMES COMMITTEE PIA

CMS REASONS FOR DELAY

- Impracticability of Implementation by April 1, 2017
 - “... the territories need time to develop and change electronic claims processing systems to identify and report utilization”
 - “Manufacturers cannot be waived from the section 1927 of the Act requirements under which manufacturers must include sales that take place in the U.S. territories when determining AMP and best price.”
 - “Drug manufacturers will likely be prompted to increase drug prices, including prices paid by U.S. territory Medicaid programs.”

MEDICAID POSSIBLE SCENARIOS



ANALYSIS, CHANGE FUNDAMENTALS

	HC Model	Funding
Current	Territorial	Territorial
Proposed	State	Territorial

ANALYSIS, CHANGE FUNDAMENTALS

HC Model



Executive
Branch

Funding



Congress

RECOMMENDATIONS

- Reasons for previous delay are still present.
- Foster Education Among all Stakeholders about relevance of this Policy.
- Address and support permanent funding solutions for Medicaid.
- Review Best Price possible implications (Contracts, Distribution)
- Evaluate Technological Infrastructure needs and readiness for implementation.
- Create Process and Task Force to deal with implementation of future Public Policies if and when applicable.